Aier Eye Hospital said in an investor relations record that in Q3 2026 the proportion of advanced procedures in its refractive segment—including ICL V5 and SMILE Pro—continued to rise, delivering significant QoQ revenue growth and materially improvin

2026-11-12

Aier Eye Hospital said in an investor relations record that in Q3 2026 the proportion of advanced procedures in its refractive segment—including ICL V5 and SMILE Pro—continued to rise, delivering significant QoQ revenue growth and materially improving the business mix.